LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
78.97
-2.28 (-2.81%)
Oct 30, 2026, 4:00 PM EDT - Market closed
LivaNova Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,472 | 1,388 | 1,253 | 1,154 | 1,022 | 1,035 |
Revenue Growth | 12.39% | 10.74% | 8.66% | 12.89% | -1.31% | 10.82% |
Gross Profit Gross Profit Growth | 996.85 | 944.07 | 854.78 | 768.42 | 707.23 | 705.99 |
Operating Income Operating Income Growth | 207.55 | 211.39 | 165.39 | 69.55 | 81.56 | 48.9 |
Net Income Net Income Growth | 188.55 | -242.47 | 63.23 | 17.55 | -86.25 | -135.82 |
Earnings Per Share EPS Growth | 3.40 | -4.45 | 1.16 | 0.32 | -1.61 | -2.68 |
EPS Growth | - | - | 262.50% | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cardiopulmonary Cardiopulmonary Growth | 840.02 | 785.39 | 683.51 | 604.11 | 514.2 | 482.98 |
Neuromodulation Neuromodulation Growth | 620.98 | 592.81 | 554.22 | 519.71 | 476.99 | 456.17 |
Other Other Growth | 10.51 | 9.86 | 15.7 | 29.72 | 30.61 | 40.76 |
Total Total Growth | 1,472 | 1,388 | 1,253 | 1,154 | 1,022 | 1,035 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 516.62 | 635.55 | 428.86 | 266.5 | 215.51 | 207.99 |
Total Debt Total Debt Growth | 351.95 | 433.77 | 676.77 | 640.4 | 580.43 | 286.7 |
Net Cash (Debt) Net Cash Growth | 164.67 | 201.78 | -247.92 | -373.9 | -364.92 | -78.71 |
Net Cash Growth | 48.54% | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 2.97 | 3.70 | -4.54 | -6.90 | -6.82 | -1.55 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 249.26 | 254.34 | 183.04 | 74.91 | 69.92 | 102.54 |
Capital Expenditures CapEx Growth | -100.95 | -81.05 | -47.11 | -34.98 | -26.52 | -25.48 |
Free Cash Flow Free Cash Flow Growth | 148.31 | 173.29 | 135.93 | 39.93 | 43.4 | 77.07 |
Free Cash Flow Growth | -8.51% | 27.48% | 240.40% | -8.00% | -43.68% | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 67.74% | 68.01% | 68.19% | 66.61% | 69.21% | 68.19% |
Operating Margin | 14.10% | 15.23% | 13.20% | 6.03% | 7.98% | 4.72% |
Pretax Margin | 7.24% | -15.91% | 7.04% | -7.05% | -7.36% | -12.04% |
Profit Margin | 12.81% | -17.47% | 5.04% | 1.52% | -8.44% | -13.12% |
FCF Margin | 10.08% | 12.48% | 10.85% | 3.46% | 4.25% | 7.44% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 23.21 | - | 39.77 | 158.85 | - | - |
Forward PE | 17.61 | 15.62 | 13.28 | 17.44 | 22.58 | 37.01 |
P/FCF Ratio | 29.34 | 19.39 | 18.50 | 69.80 | 68.49 | 60.38 |
PS Ratio | 2.96 | 2.42 | 2.01 | 2.42 | 2.91 | 4.50 |